(Circulation. 2000;101:e182.)
© 2000 American Heart Association, Inc.
Circulation Electronic Pages |
Cell Transplantation as Future Therapy for Cardiovascular Disease?
A Workshop of the National Heart, Lung, and Blood Institute
From the Division of Heart and Vascular Diseases, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md (L.R.), and the Krannert Institute of Cardiology and Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Ind (L.F.).
Correspondence to Leslie Reinlib, PhD, Division of Heart and Vascular Diseases, National Heart, Lung, and Blood Institute, Rockledge Center Two, 6701 Rockledge Drive, Bethesda, MD 20892-7940. E-mail lr25v{at}nih.gov
Abstract—Despite the development of improved therapies and the significant advances in the understanding of the basis of disease pathogenesis, millions of Americans continue to live with life-threatening cardiovascular diseases. Recent breakthroughs suggest exciting directions that are likely to produce more effective therapies for the treatment of cardiovascular disease. One such area, cell transplantation (grafting of healthy cells into the diseased heart), holds enormous potential as an approach to cardiovascular pathophysiology. Once thought to be a scientific long shot, cell transplantation is becoming recognized as a viable strategy to strengthen weak hearts and limit infarct growth. The technology could also be used for the long-term delivery of beneficial recombinant proteins to the heart, which is a strategy to complement molecular biology advances and provide an alternative strategy for gene therapy. On August 24, 1998, the National Heart, Lung, and Blood Institute convened a workshop to discuss the current status of this fast-moving line of research and to explore its promise for treating cardiovascular disease. The participants included basic and clinical researchers, with representatives from academic and commercial research settings. The workshop was designed to establish the state-of-the-art and to equate current research with practical clinical application. The group recommended short- and long-term goals to assist in realizing, in the most expedient manner, the potential utility of cell transplantation for the treatment of cardiovascular disease. A summary of the meeting discussions and recommendations for future areas of research is presented.
Key Words: cardiovascular diseases • cells • grafting • myocytes
This article has been cited by other articles:
 |
|
 |
|
  M. Rubart, E. Wang, K. W. Dunn, and L. J. Field Two-photon molecular excitation imaging of Ca2+ transients in Langendorff-perfused mouse hearts Am J Physiol Cell Physiol, June 1, 2003; 284(6): C1654 - C1668. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Miyagawa, Y. Sawa, S. Taketani, N. Kawaguchi, T. Nakamura, N. Matsuura, and H. Matsuda Myocardial Regeneration Therapy for Heart Failure: Hepatocyte Growth Factor Enhances the Effect of Cellular Cardiomyoplasty Circulation, May 28, 2002; 105(21): 2556 - 2561. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Grounds, J. D. White, N. Rosenthal, and M. A. Bogoyevitch The Role of Stem Cells in Skeletal and Cardiac Muscle Repair J. Histochem. Cytochem., May 1, 2002; 50(5): 589 - 610. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Shimizu, M. Yamato, Y. Isoi, T. Akutsu, T. Setomaru, K. Abe, A. Kikuchi, M. Umezu, and T. Okano Fabrication of Pulsatile Cardiac Tissue Grafts Using a Novel 3-Dimensional Cell Sheet Manipulation Technique and Temperature-Responsive Cell Culture Surfaces Circ. Res., February 22, 2002; 90 (3): e40 - e48. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. B. S. Pasumarthi, S.-C. Tsai, and L. J. Field Coexpression of Mutant p53 and p193 Renders Embryonic Stem Cell-Derived Cardiomyocytes Responsive to the Growth-Promoting Activities of Adenoviral E1A Circ. Res., May 25, 2001; 88(10): 1004 - 1011. [Abstract] [Full Text] [PDF]
|
|